Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label first-in-human dose-escalation study of intracranial SI-053 in newly diagnosed glioblastoma
NL-OMON51969Phase 1Not yet recruiting
- Sponsor
- Double Bond Pharmaceutical
- Start
- Jan 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Temodex in glioblastoma (GBM), sponsored by Double Bond Pharmaceutical. Primary endpoints: Dose-limiting toxicities and SI-053-related safety and toxicity. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
Temodex
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON51969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51969.